HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRES	CRIBER		PATIENT:
Name	e:		Name:
Ward	:		NHI:
Pirfenidone			
Re-a	ssessmer equisites Pres	Patient has been diagnosed with idiopathic pulmonary fibrosis Forced vital capacity is between 50% and 90% predicted Pirfenidone is to be discontinued at disease progression (See Pirfenidone is not to be used in combination with subsidised n O The patient has not previously received treatment with r O Patient has previously received nintedanib, but disconting	Notes) iintedanib nintedanib nued nintedanib within 12 weeks due to intolerance ent's disease has not progressed (disease progression defined as 10%
		or more desime in produced in to waim any 12 monary	Silve share starting treatment with timitedams)
CONTINUATION – idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.			
	and on and	Treatment remains clinically appropriate and patient is benefit: Pirfenidone is not to be used in combination with subsidised in Pirfenidone is to be discontinued at disease progression (See	nintedanib
Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.			

I confirm that the above details are correct:

Signed: Date: